The coming Monday, 6 March, is a key date in the diary for Alvotech – potentially, a watershed moment for the firm that could decide whether it is able to join in a timely fashion the glut of second wave adalimumab biosimilars set to launch in the US later this year.
On that day, the US Food and Drug Administration will begin its re-inspection of the firm’s manufacturing facility in Reykjavik,...






